276 related articles for article (PubMed ID: 7555036)
41. Rifaximin for the treatment of hepatic encephalopathy.
de Melo RT; Charneski L; Hilas O
Am J Health Syst Pharm; 2008 May; 65(9):818-22. PubMed ID: 18436728
[TBL] [Abstract][Full Text] [Related]
42. Antibiotics With or Without Rifaximin for Acute Hepatic Encephalopathy in Critically Ill Patients With Cirrhosis: A Double-Blind, Randomized Controlled (ARiE) Trial.
Kulkarni AV; Avadhanam M; Karandikar P; Rakam K; Gupta A; Simhadri V; Premkumar M; Zuberi AA; Gujjarlapudi D; Narendran R; Shaik S; Sharma M; Iyengar S; Alla M; Venishetty S; Reddy DN; Rao PN
Am J Gastroenterol; 2024 May; 119(5):864-874. PubMed ID: 37942950
[TBL] [Abstract][Full Text] [Related]
43. A non-absorbable rifamycin for treatment of hepatic encephalopathy.
Testa R; Eftimiadi C; Sukkar GS; De Leo C; Rovida S; Schito GC; Celle G
Drugs Exp Clin Res; 1985; 11(6):387-92. PubMed ID: 3836135
[TBL] [Abstract][Full Text] [Related]
44. Review article: the current pharmacological therapies for hepatic encephalopathy.
Bass NM
Aliment Pharmacol Ther; 2007 Feb; 25 Suppl 1():23-31. PubMed ID: 17295849
[TBL] [Abstract][Full Text] [Related]
45. Small Intestinal Bacterial Overgrowth Diagnosed by a Breath Test and Improved by Rifaximin in a Patient with Hepatic Encephalopathy and Alcoholic Liver Cirrhosis.
Sakamaki A; Yokoyama K; Yamazaki F; Kamimura H; Kamimura K; Takamura M; Yokoyama J; Terai S
Intern Med; 2020 Aug; 59(15):1849-1853. PubMed ID: 32321898
[TBL] [Abstract][Full Text] [Related]
46. [Pay more attention to hepatic encephalopathy].
Labenz J
MMW Fortschr Med; 2014 Feb; 156(2):60-1. PubMed ID: 24934059
[No Abstract] [Full Text] [Related]
47. Evolving concepts: the negative effect of minimal hepatic encephalopathy and role for prophylaxis in patients with cirrhosis.
Prakash RK; Kanna S; Mullen KD
Clin Ther; 2013 Sep; 35(9):1458-73. PubMed ID: 23972578
[TBL] [Abstract][Full Text] [Related]
48. Pharmacotherapy for hepatic encephalopathy.
Phongsamran PV; Kim JW; Cupo Abbott J; Rosenblatt A
Drugs; 2010 Jun; 70(9):1131-48. PubMed ID: 20518580
[TBL] [Abstract][Full Text] [Related]
49. Rifaximin vs. conventional oral therapy for hepatic encephalopathy: a meta-analysis.
Eltawil KM; Laryea M; Peltekian K; Molinari M
World J Gastroenterol; 2012 Feb; 18(8):767-77. PubMed ID: 22371636
[TBL] [Abstract][Full Text] [Related]
50. Treatment of Acute Hepatic Encephalopathy: Comparing the Effects of Adding Rifaximin to Lactulose on Patient Outcomes.
Courson A; Jones GM; Twilla JD
J Pharm Pract; 2016 Jun; 29(3):212-7. PubMed ID: 25586470
[TBL] [Abstract][Full Text] [Related]
51. Combination of rifaximin and lactulose improves clinical efficacy and mortality in patients with hepatic encephalopathy.
Wang Z; Chu P; Wang W
Drug Des Devel Ther; 2019; 13():1-11. PubMed ID: 30587923
[TBL] [Abstract][Full Text] [Related]
52. Treatment options for hepatic encephalopathy.
Schiano TD
Pharmacotherapy; 2010 May; 30(5 Pt 2):16S-21S. PubMed ID: 20412036
[TBL] [Abstract][Full Text] [Related]
53. Update on management of patients with overt hepatic encephalopathy.
Chacko KR; Sigal SH
Hosp Pract (1995); 2013 Aug; 41(3):48-59. PubMed ID: 23948621
[TBL] [Abstract][Full Text] [Related]
54. A Quality Improvement Initiative Reduces 30-Day Rate of Readmission for Patients With Cirrhosis.
Tapper EB; Finkelstein D; Mittleman MA; Piatkowski G; Chang M; Lai M
Clin Gastroenterol Hepatol; 2016 May; 14(5):753-9. PubMed ID: 26407750
[TBL] [Abstract][Full Text] [Related]
55. Efficacy of rifaximin in the different clinical scenarios of hepatic encephalopathy.
Coronel-Castillo CE; Contreras-Carmona J; Frati-Munari AC; Uribe M; Méndez-Sánchez N
Rev Gastroenterol Mex (Engl Ed); 2020; 85(1):56-68. PubMed ID: 31836274
[TBL] [Abstract][Full Text] [Related]
56. Rifaximin: a review of its use in reducing recurrence of overt hepatic encephalopathy episodes.
Scott LJ
Drugs; 2014 Dec; 74(18):2153-60. PubMed ID: 25352391
[TBL] [Abstract][Full Text] [Related]
57. Dosing of Rifaximin Soluble Solid Dispersion Tablets in Adults With Cirrhosis: 2 Randomized, Placebo-controlled Trials.
Bajaj JS; Hassanein TI; Pyrsopoulos NT; Sanyal AJ; Rahimi RS; Heimanson Z; Israel RJ; Rockey DC
Clin Gastroenterol Hepatol; 2023 Mar; 21(3):723-731.e9. PubMed ID: 35750249
[TBL] [Abstract][Full Text] [Related]
58. Rifaximin versus nonabsorbable disaccharides in the management of hepatic encephalopathy: a meta-analysis.
Jiang Q; Jiang XH; Zheng MH; Jiang LM; Chen YP; Wang L
Eur J Gastroenterol Hepatol; 2008 Nov; 20(11):1064-70. PubMed ID: 19047837
[TBL] [Abstract][Full Text] [Related]
59. Comparison of once a day rifaximin to twice a day dosage in the prevention of recurrence of hepatic encephalopathy in patients with chronic liver disease.
Khokhar N; Qureshi MO; Ahmad S; Ahmad A; Khan HH; Shafqat F; Salih M
J Gastroenterol Hepatol; 2015 Sep; 30(9):1420-2. PubMed ID: 25867912
[TBL] [Abstract][Full Text] [Related]
60. Enhancement of functional connectivity, working memory and inhibitory control on multi-modal brain MR imaging with Rifaximin in Cirrhosis: implications for the gut-liver-brain axis.
Ahluwalia V; Wade JB; Heuman DM; Hammeke TA; Sanyal AJ; Sterling RK; Stravitz RT; Luketic V; Siddiqui MS; Puri P; Fuchs M; Lennon MJ; Kraft KA; Gilles H; White MB; Noble NA; Bajaj JS
Metab Brain Dis; 2014 Dec; 29(4):1017-25. PubMed ID: 24590688
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
